Brokerages expect Neurocrine Biosciences, Inc. (NASDAQ:NBIX) to report $0.05 earnings per share (EPS) for the current fiscal quarter, according to Zacks Investment Research. Eight analysts have provided estimates for Neurocrine Biosciences’ earnings, with estimates ranging from ($0.21) to $0.39. Neurocrine Biosciences reported earnings per share of ($0.51) during the same quarter last year, which would suggest a positive year over year growth rate of 109.8%. The firm is scheduled to announce its next earnings report on Tuesday, February 13th.

According to Zacks, analysts expect that Neurocrine Biosciences will report full year earnings of ($1.66) per share for the current year, with EPS estimates ranging from ($2.00) to ($1.31). For the next year, analysts expect that the firm will post earnings of ($0.24) per share, with EPS estimates ranging from ($1.36) to $2.00. Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of sell-side research analysts that follow Neurocrine Biosciences.

Neurocrine Biosciences (NASDAQ:NBIX) last issued its quarterly earnings data on Wednesday, November 1st. The company reported ($0.13) EPS for the quarter, topping the consensus estimate of ($0.49) by $0.36. The company had revenue of $60.77 million during the quarter, compared to analysts’ expectations of $29.38 million. During the same period last year, the company earned ($0.43) earnings per share.

A number of brokerages recently commented on NBIX. Jefferies Group increased their price target on Neurocrine Biosciences to $105.00 and gave the company a “buy” rating in a research report on Friday. Oppenheimer increased their price target on Neurocrine Biosciences from $70.00 to $85.00 and gave the company an “outperform” rating in a research report on Thursday, November 2nd. Citigroup reissued a “buy” rating and set a $79.00 price objective on shares of Neurocrine Biosciences in a report on Thursday, November 2nd. Needham & Company LLC reissued a “buy” rating and set a $86.00 price objective on shares of Neurocrine Biosciences in a report on Thursday, November 2nd. Finally, Piper Jaffray Companies reissued a “buy” rating and set a $76.00 price objective on shares of Neurocrine Biosciences in a report on Wednesday, October 25th. One equities research analyst has rated the stock with a hold rating and eighteen have given a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus target price of $81.13.

In related news, insider Dimitri E. Grigoriadis sold 30,000 shares of the firm’s stock in a transaction dated Wednesday, November 8th. The stock was sold at an average price of $74.58, for a total value of $2,237,400.00. Following the sale, the insider now directly owns 77,691 shares of the company’s stock, valued at $5,794,194.78. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Kyle Gano sold 24,818 shares of the firm’s stock in a transaction dated Thursday, November 2nd. The stock was sold at an average price of $71.05, for a total value of $1,763,318.90. Following the completion of the sale, the insider now directly owns 84,596 shares in the company, valued at $6,010,545.80. The disclosure for this sale can be found here. In the last quarter, insiders sold 116,405 shares of company stock worth $8,588,519. Company insiders own 4.80% of the company’s stock.

A number of institutional investors have recently bought and sold shares of NBIX. The Manufacturers Life Insurance Company boosted its position in Neurocrine Biosciences by 7.8% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 2,665 shares of the company’s stock valued at $123,000 after acquiring an additional 193 shares in the last quarter. Stephens Inc. AR bought a new stake in Neurocrine Biosciences during the 2nd quarter valued at approximately $207,000. Comerica Bank bought a new stake in Neurocrine Biosciences during the 3rd quarter valued at approximately $210,000. Ardsley Advisory Partners bought a new stake in Neurocrine Biosciences during the 2nd quarter valued at approximately $230,000. Finally, Cubist Systematic Strategies LLC boosted its position in Neurocrine Biosciences by 151.5% during the 2nd quarter. Cubist Systematic Strategies LLC now owns 5,301 shares of the company’s stock valued at $244,000 after acquiring an additional 3,193 shares in the last quarter.

Shares of Neurocrine Biosciences (NASDAQ:NBIX) traded up $1.45 on Thursday, hitting $81.73. The company had a trading volume of 895,351 shares, compared to its average volume of 819,827. The company has a debt-to-equity ratio of 1.05, a current ratio of 14.38 and a quick ratio of 14.37. Neurocrine Biosciences has a one year low of $38.43 and a one year high of $83.57.

WARNING: This piece of content was originally published by Marea Informative and is the property of of Marea Informative. If you are reading this piece of content on another publication, it was illegally stolen and republished in violation of US and international copyright law. The correct version of this piece of content can be viewed at https://www.mareainformativa.com/2018/01/30/neurocrine-biosciences-inc-nbix-expected-to-post-earnings-of-0-05-per-share-updated-updated-updated.html.

About Neurocrine Biosciences

Neurocrine Biosciences, Inc is engaged in discovering and developing pharmaceuticals, in diseases with unmet medical needs, through its research and development (R&D) platform, focused on neurological and endocrine based diseases and disorders. Its three lead late-stage clinical programs are elagolix, which is a gonadotropin-releasing hormone (GnRH) antagonist for endometriosis and uterine fibroids; INGREZZA (valbenazine), which is a vesicular monoamine transporter 2 (VMAT2) inhibitor, for the treatment of movement disorders, and opicapone, which is a selective catechol-O-methyltransferase inhibitor that is an adjunct therapy to preparations of levodopa/Dihydroxyphenylalanine (DOPA) decarboxylase inhibitors for adult patients with Parkinson’s disease.

Get a free copy of the Zacks research report on Neurocrine Biosciences (NBIX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Neurocrine Biosciences (NASDAQ:NBIX)

Receive News & Ratings for Neurocrine Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.